Cathepsin
Inhibitors Market, by Product Type (Cathepsin S Inhibitors, Cathepsin K
Inhibitors, Cathepsin B Inhibitors, Cathepsin L Inhibitors, and Others), by
Indication (Cancer, Traumatic Brain Injury, Ebola Infection, and Others), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018
– 2026
Cathepsins are a group of
lysosomal proteases (enzymes that degrades protein), found in all animals and
other organisms, and perform a key role in cellular protein turnover. Cathepsin
family includes serine proteases, aspartic proteases, and cysteine proteases.
The aspartyl protease class is composed of cathepsins D and E. The cysteine
protease class comprises cathepsins B, L, H, K, S, and O. Cathepsin G includes
serine protease class. Currently, there are no approved cathepsin inhibitors in
the market, however various research and development activities are under
process for the development of novel cathepsin inhibitors for treatment of
various conditions such as cancer, traumatic brain injury, Ebola infection, and
others.
Cathepsin Inhibitors Market
Drivers
Various key players in the market
are conducting clinical trials to gain approval for cathepsin inhibitors, which
are under development phase and are expected to gain approval in the near
future.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2306
For instance, Merck Sharp &
Dohme Corp.’s product, Odanacatib, also known as MK-0822, is under Phase 2
clinical trial. MK-0822 is a cathepsin K inhibitor under development for the treatment
of postmenopausal women with osteoporosis. Hence, presence of novel products in
the pipeline is expected to significantly support growth of the cathepsin
inhibitors market during the forecast period.
Furthermore, high prevalence of
diseases for which cathepsin inhibitors are being developed may rise demand for such novel treatment
approaches in the near future. For instance, according to the data published by
Centers of Disease Control and Prevention in 2017, traumatic brain injury (TBI)
is a major cause of death and disability in the U.S. TBIs contribute to about
30% of all injury deaths. 153 people in the U.S. die per day, from injuries
that include TBI.
Cathepsin Inhibitors Market
Regional Analysis
North America cathepsin
inhibitors market is expected to hold a dominant position in the global
cathepsin inhibitors market, owing to the high prevalence of disease such as
cancer, which will increase demand for novel cancer treatment approaches such
as cathepsin inhibitors in region.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/cathepsin-inhibitors-market-2306
For instance, according to the
data published by National Cancer Institute, it was estimated that in 2018,
around 1,735,350 new cases of cancer will be diagnosed in the U.S. and around
609,640 people will die from the disease.
Europe cathepsin inhibitors
market is also expected to show a significant growth during the forecast
period, owing to frequent research and development activities by key players
for the development of new cathepsin inhibitors in the region. For instance, F.
Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, is developing
RO5459072, a cathepsin S inhibitor, on the immune response to a gluten
challenge in volunteers with celiac disease.
Cathepsin Inhibitors Market Key
Players
Key players operating in global
cathepsin inhibitors market include F. Hoffmann-La Roche AG, Merck Sharp &
Dohme Corp., Virobay Inc., LEO Pharma, and others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2306
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment